Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
Titration Target for Chinese Type 2 Diabetes Mellitus Patients Using Insulin Glargine to Achieve Glycaemic Goals: An Assessment of Three Different Fasting Plasma Glucose Targets - BEYOND III/FPG GOAL Study
Primary Objective:
To identify a best fasting plasma glucose (FPG) target for Chinese type 2 diabetes patients using insulin glargine which can provide the highest control rate of glycated hemoglobin (HbA1c) < 7%.
Secondary Objectives:
The control rate of HbA1c ≤6.5% achievement. The control rate of HbA1c <7.0% in patients achieving their FPG target. The percentage of HbA1c <7% without hypoglycemia. The percentage of patients achieving the FPG target without hypoglycemia. The percentage of patients achieving the FPG target and post prandial glucose (PPG) target (2-hour post breakfast <10 mmol/L).
調査の概要
詳細な説明
研究の種類
入学 (実際)
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
-
Anshan、中国
- Investigational Site Number 156053
-
Beijing、中国
- Investigational Site Number 156006
-
Beijing、中国
- Investigational Site Number 156001
-
Beijing、中国
- Investigational Site Number 156002
-
Changchun、中国、130033
- Investigational Site Number 156013
-
Changchun、中国、130033
- Investigational Site Number 156014
-
Changde、中国、415000
- Investigational Site Number 156022
-
Changsha、中国
- Investigational Site Number 156017
-
Changzhou、中国
- Investigational Site Number 156034
-
Chenzhou、中国
- Investigational Site Number 156023
-
Guangzhou、中国、510515
- Investigational Site Number 156026
-
Haikou、中国、570102
- Investigational Site Number 156029
-
Haikou、中国
- Investigational Site Number 156028
-
Haikou、中国
- Investigational Site Number 156040
-
Hangzhou、中国、310013
- Investigational Site Number 156039
-
Hangzhou、中国
- Investigational Site Number 156038
-
Hangzhou、中国
- Investigational Site Number 156042
-
Hangzhou、中国
- Investigational Site Number 156044
-
Hefei、中国
- Investigational Site Number 156048
-
Hefei、中国
- Investigational Site Number 156050
-
Kunming、中国
- Investigational Site Number 156011
-
Kunming、中国
- Investigational Site Number 156052
-
Lanzhou、中国
- Investigational Site Number 156016
-
Lishui、中国
- Investigational Site Number 156041
-
Nanchang、中国、330006
- Investigational Site Number 156020
-
Nanchang、中国
- Investigational Site Number 156018
-
Nanchang、中国
- Investigational Site Number 156019
-
Nanjing、中国
- Investigational Site Number 156031
-
Nanjing、中国
- Investigational Site Number 156043
-
Nanjing、中国
- Investigational Site Number 156049
-
Shanghai、中国
- Investigational Site Number 156035
-
Shanghai、中国
- Investigational Site Number 156036
-
Shanghai、中国
- Investigational Site Number 156047
-
Shantou、中国
- Investigational Site Number 156027
-
Shenyang、中国
- Investigational Site Number 156015
-
Shijiazhuang、中国
- Investigational Site Number 156054
-
Tangshan、中国、063000
- Investigational Site Number 156007
-
Tianjin、中国、300032
- Investigational Site Number 156010
-
Wuhan、中国、430000
- Investigational Site Number 156055
-
Xuzhou、中国
- Investigational Site Number 156037
-
Yangzhou、中国
- Investigational Site Number 156033
-
Yueyang、中国
- Investigational Site Number 156030
-
Zhenjiang、中国、212001
- Investigational Site Number 156032
-
Zhuzhou、中国、412000
- Investigational Site Number 156025
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria :
- 18 to 65 years old.
- Type 2 diabetes patients insufficient controlled by 1-3 oral anti-hyperglycemic drugs (OADs) with stable dose at least 3 months:
If on 1 OAD, provided with the following doses (including but not limited to):
- α-glucosidase inhibitor: 100mg, three times a day (tid);
- metformin: 1.5-2.0 g/day;
- sulphonylureas: sub-maximum (half dose above) to maximum tolerated dose;
- thiazolidinediones: eg. pioglitazone, 30-40 mg/day.
- Besides the medications listed above, if on 1 OAD, others should be maximum tolerated dose allowed in package insert.
- If on 2-3 OADs, any range of dose is acceptable.
- HbA1c >7%, and ≤10.5%.
- FPG >7 mmol/L.
- Body mass index (BMI) ≥20 kg/m^2, and ≤40 kg/m^2.
- Diabetes duration ≥1 year.
- Physician decides to and the patient is willing to start basal insulin (BI) treatment.
- Willing to join the study and sign the informed consent.
Exclusion criteria:
- Type 1 diabetes patients.
- Patients with acute diabetic complications (including unexplained severe hypoglycemia in the last 6 months).
- Previous treatment with insulin for more than 1 month cumulatively in last 1 year, or treatment with insulin in the last 3 months before the screening.
- Known hypoglycemia unawareness or recurrent hypoglycemia.
- Hypersensitivity to study drug or its excipients.
- Any clinically significant acute major organ or systemic disease, or any other situation judged by the Investigator, that is difficult for the 24 weeks follow-up.
- Pregnancy or breastfeeding women.
- Have any mental disorders, lack self-control or not able to express accurately.
- Involved in another clinical trial simultaneously or within a 1 month before start of trial.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Group 1
Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=5.6 mmol/L
|
Pharmaceutical form: solution Route of administration: subcutaneous
他の名前:
|
実験的:Group 2
Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=6.1 mmol/L
|
Pharmaceutical form: solution Route of administration: subcutaneous
他の名前:
|
実験的:Group 3
Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=7.0 mmol/L
|
Pharmaceutical form: solution Route of administration: subcutaneous
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
Percentage of patients with HbA1c <7% achievement
時間枠:24 weeks
|
24 weeks
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
Percentage of patients achieving HbA1c <=6.5%
時間枠:24 weeks
|
24 weeks
|
Percentage of patients achieving FPG target with HbA1c <7%
時間枠:24 weeks
|
24 weeks
|
Percentage of patients achieving HbA1c <7% without hypoglycemia
時間枠:24 weeks
|
24 weeks
|
Percentage of patients achieving the FPG target without hypoglycemia
時間枠:24 weeks
|
24 weeks
|
Percentage of patients achieving FPG target
時間枠:24 weeks
|
24 weeks
|
Percentage of patients achieving PPG target (2-hour post-breakfast <10 mmol/L)
時間枠:24 weeks
|
24 weeks
|
Change from baseline in HbA1c
時間枠:Baseline to 24 weeks
|
Baseline to 24 weeks
|
Change in FPG
時間枠:8 weeks to 24 weeks
|
8 weeks to 24 weeks
|
Change in PPG
時間枠:Baseline to 24 weeks
|
Baseline to 24 weeks
|
Change in insulin doses in each arm
時間枠:1 week to 24 weeks
|
1 week to 24 weeks
|
Change in body weight in each treatment arm
時間枠:Baseline to 24 weeks
|
Baseline to 24 weeks
|
Percentage of patients experienced hypoglycemic events
時間枠:24 weeks
|
24 weeks
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- Wang X, Wu G, Shen D, Zhang X, Yang W. Unmet Needs of Glycaemic Control and Risk Factors of Residual Hyperglycaemia in a Chinese Population with Type 2 Diabetes Initiating Basal Insulin: A Post Hoc Analysis of the FPG GOAL Study. Adv Ther. 2022 Jun;39(6):2820-2830. doi: 10.1007/s12325-022-02128-y. Epub 2022 Apr 16.
- Li L, Yang T, Xue Y, Ruan P, Du J, Li Y, Zhang X, Cui N, Yang W. Influence of Fasting Plasma Glucose Targets on Glycemic Variability in Chinese Participants With Type 2 Diabetes: A Post Hoc Analysis of the FPG GOAL Trial (BEYOND III). Adv Ther. 2022 Jan;39(1):421-429. doi: 10.1007/s12325-021-01932-2. Epub 2021 Nov 10.
- Ma J, Lei M, Li Y, Zhang X, Cui N, Yang W. Influence of Fasting Glucose Levels on Achieving Glycemic Target in Individuals with Type 2 Diabetes: a Post Hoc Analysis. Adv Ther. 2020 Sep;37(9):3816-3826. doi: 10.1007/s12325-020-01410-1. Epub 2020 Jul 15.
- Yang W, Yang Z, Zhao J, Lu H, Luo T. Assessment of three fasting plasma glucose targets for insulin glargine-based therapy in people with type 2 diabetes mellitus in China: study protocol for a randomized controlled trial. Trials. 2016 Sep 26;17(1):470. doi: 10.1186/s13063-016-1588-6.
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- LANTUL07190
- U1111-1172-1058 (その他の識別子:UTN)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
2型糖尿病の臨床試験
INSULIN GLARGINEの臨床試験
-
Julphar Gulf Pharmaceutical IndustriesParexel; Profil Institut für Stoffwechselforschung GmbH完了
-
Julphar Gulf Pharmaceutical IndustriesProfil Institut für Stoffwechselforschung GmbH完了
-
Sanofi終了しました
-
Emory UniversityBoston Medical Center; Rush University; University of Denver完了
-
Emory UniversityMerck Sharp & Dohme LLC; University of Michigan; Temple University; Ohio University完了